Abstract D-Penicillamine inhibited oxidant secretion from human neutrophils after activation by the chemotactic peptide N-formyl-methionylleucyl-phenylalanine (fMet-Leu-Phe), as assessed by luminol dependent chemiluminescence. In contrast, this drug had little effect on eitherintraceliular oxidant production or lucigenin dependent chemiluminescence activated by the same agonist. The drug was shown to scavenge both H202 and HOCI in a cell free luminol chemiluminescence system, though its ability to scavenge HOCI was greater than that for H202. Both these oxidants could oxidise the drug, but again HOCI was more potent than H202. When D-penicidlamine was oxidised by exposure to H202 it could no longer serve as a scavenger of secreted oxidants from neutrophils. These data suggest that in vivo the preferential scavenging of HOCI may be important under pathological conditions where secreted myeloperoxidase may be functional.
D-Penicillamine is a slow acting drug used in the treatment of rheumatoid arthritis, but despite its widespread use its biological mode of action remains obscure. Several mechanisms have been proposed to explain its efficacy, including effects of collagen metabolism,' immunopathological effects in the presence of copper,2 superoxide dismutase activity,3 and ability to scavenge H202 and HOC1,4 both of which are products of activated phagocytes. Furthermore, a more direct inhibitory effect of this drug on the activity of the neutrophil enzyme myeloperoxidase has been proposed as it can promote the formation of compound III, which is inactive in the generation of HOCL. 7 In view of the fact that neutrophils within inflamed joints of patients with rheumatoid arthritis have been activated to secrete reactive oxidants"'0 and myeloperoxidase,"1 12 one explanation for the therapeutic activity of Dpenicillamine may reside in its ability to scavenge the neutrophil products H202 and HOC1 within such joints. However, only modest inhibitory effects of this drug on neutrophil dependent oxidant production have been described. For example, after stimulation of neutrophils by phorbol myristate acetate, D-penicillamine at 0-1 mmol/l only inhibited the activated chemiluminescence by 20%,'3 and when opsonised zymosan was used as the stimulus the drug was reported to enhance the chemiluminescence response. 4 These observations thus seem to contradict the view that D-penicillamine is an effective oxidant scavenger.
We have previously shown that activated neutrophils generate reactive oxidants both intra-and extracellularly,'5 and that these two activities are dependent upon the nature of the stimulus used. For example, the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMet-Leu-Phe) stimulates a rapid burst of oxidant secretion which is followed by a second phase of internally generated oxidants, whereas phagocytic stimuli, such as immune complexes or opsonised zymosan, activate oxidant production which is largely intracellular. Furthermore, the extent of myeloperoxidase secretion (and hence ability to constitute an extracellular myeloperoxidase-H202 system) is also dependent upon the nature of the neutrophil activating factor. Thus one explanation for the reports of an apparently low ability of D-penicillamine to scavenge neutrophil derived oxidants is that the experimental conditions used largely activated intracellular oxidant production, which may be inaccessible to the drug. This work aimed at establishing if D-penicillamine scavenged extracellularly released neutrophil oxidants (as these are likely to be of importance in inflammatory joint disease) and measuring the relative affinities of the drug for H202 and HOCI to determine its effects on oxidant production, dependent and independent of myeloperoxidase. CHEMICALS D-Penicillamine, luminol, lucigenin, fMet-LeuPhe, and H202 were from Sigma, and HOC1 was from BDH. Before analyses freshly prepared solutions of H202 and HOCI were quantified by measurement of their absorption at 240 and 290 nm, respectively, using molar absorption coefficients of 43-4 and 390, respectively.
Results

EFFECT OF D-PENICILLAMINE ON FMET-LEU-PHE STIMULATED NEUTROPHIL CHEMILUMINESCENCE
When neutrophil suspensions are stimulated by the chemotactic peptide fMet-Leu-Phe the luminol dependent chemiluminescence response, which requires the activities of both the O2-/H202 generating oxidase and myeloperoxidase,'7 is biphasic. We have shown that the initial, rapid (within one minute) peak is 1 5 0 largely due to oxidant secretion, whereas the second, more sustained phase of oxidant production is largely intracellular.'5 When neutrophil suspensions were preincubated with D-penicillamine for two min before addition of fMet-Leu-Phe the chemiluminescence responses generated were reduced in the presence of the drug (figs 1A and 2). The effects of the drug on intra-and extracellular luminol chemiluminescence were not identical, however: for example, at a drug concentration of 10' mol/l the extracellular (initial) oxidant production was inhibited by 72%, whereas the intracellular production (that detected between three and five minutes) was only inhibited by 31% ( Fig  IA) . There was little difference in the inhibitory effects of different concentrations of D-penicillamine on intracellular oxidant production, whereas a clear inhibition of extracellular secretion dependent on dose was seen (fig 2) .
In Effect ofD-penicillamine on intra-and extracellular oxidant production. Neutrophils (106/ml) were suspended in buffer containing 10 scavenged O°either generated in a cell free xanthine/xanthine oxidase system or else secreted from activated neutrophils, by determining its effects on cytochrome c reduction were frustrated by the fact that the drug itself rapidly reduced the cytochrome c. The ability of the drug to scavenge H202 and HOCI was determined using a cell free chemiluminescence system.'8 The system is based on the fact that when HOCI is added to mixtures of H202 and luminol a rapid chemiluminescence burst is initiated. Preincubation of the H202/luminol mixture with D-penicillamine reduced the chemiluminescence response initiated by HOC1 by about 50% ( :Number of determinations is given (n) together with the standard deviation. (fig 4) then the oxidised drug should have little or no effect on neutrophil function. Thus a solution of D-penicillamine was mixed with just sufficient H202 for its complete oxidation, and its ability to scavenge neutrophil derived oxidants generated in response to fMet-Leu-Phe was determined. Whereas the native (reduced) drug inhibited oxidant secretion by over 60%, the oxidised form of the drug had no effect on oxidant secretion (fig 5) . These data confirm that D-penicillamine scavenges secreted oxidants, thus reducing oxidant production by neutrophils, itself becoming oxidised (and nonfunctional) in the process. 
Discussion
The data presented in this paper confirm that Dpenicillamine is a potent scavenger of both H202 and HOC1, two products of the respiratory burst of activated neutrophils. As the relative concentrations of these two oxidants at inflammatory sites will depend on the levels of extracellular activity of the Oi/H202 generating NADPH oxidase and the activity of secreted myeloperoxidase, it is important to identify the potency of D-penicillamine in scavenging both H202 and HOCI. We have shown here that on a molar basis D-penicillamine is at least twice as efficient at scavenging HOCI than at scavenging H202. This may be of pathological importance as we have previously shown that although neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis have been activated in vivo to secrete reactive oxidants,'0 they have also been activated to secrete myeloperoxidase in these joints, and the myeloperoxidase is in a molecular form which indicates that it has reacted with H202.l" Furthermore, factor(s) present within synovial fluid can activate the myeloperoxidase-H202 system,'2 and hence the ability of D-penicillamine to scavenge HOC1 within the inflamed joint may be of more importance than its ability to detoxify H202.
Previous work has shown only a modest inhibitory effect of D-penicillamine on phorbol myristate acetate stimulated luminol chemiluminescence of neutrophils,'3 and even a stimulatory effect on opsonised zymosan activated chemiluminescence,'4 despite the fact that the drug efficiently scavenges oxidants in cell free systems. Neither of these experimental conditions, however, results in optimal secretion of reactive oxidants from neutrophils. In our study we used the chemotactic peptide fMetLeu-Phe to stimulate neutrophils because this agonist activates clearly defined phases of oxidant secretion (detected within one minute of addition) followed by intracellular oxidant production.'5 Under these conditions 0I mol/l D-penicillamine inhibited oxidant secretion by over 70% (fig 1) , compared with only 20% inhibitionofphorbolmyristate acetate stimulated luminol chemiluminescence.'3 The drug had little effect on intracellular oxidant production and this phenomenon was not dependent on concentration. The biological function of such intracellular oxidant generation and the significance of the effects of D-penicillamine on this phenomenon are unknown.
Luminol chemiluminescence requires the activity of the myeloperoxidase.-H202 system, whereas lucigenin is thought to measure only O°o r H202 secretion, or both,'7 though the precise molecular species reacting with the latter lumigenic probe has not been unambiguously defined. Therefore, it is of considerable interest to note that although E-penicillamine scavenged extracellular luminol chemiluminescence, it had little effect on lucigenin chemiluminescence (fig 1) . This implies that either lucigenin does not in fact measure Oj or H202, or else that the predominant effect of D-penicillamine in neutrophils is to scavenge a myeloperoxidase dependent product (that is, HOCI) rather than H202. Therefore, we tested for the ability of Dpenicillamine to scavenge both H202 and HOCI and found that it is a more potent scavenger of the latter oxidant.
The ability of D-penicillamine to scavenge H202 and HOCI resides in its thiol group. The drug becomes oxidised during its interaction with oxidants, and the oxidised form of the drug is incapable of interfering with the processes of neutrophil oxidant production. Although the serum concentration of this drug may be as high as 20 Vmol/1,20 its effective concentration within joints, which may be exposed to high levels of neutrophil derived oxidants, will be reduced owing to its oxidation, and this may be of pathological importance. In view ofthe emerging evidence indicating that an extracellular myeloperoxidase-H202 system is operational in the rheumatoid joint, scavenging of HOCI (and to a lesser extent H202) may be one means by which the efficacy of this drug is explained.
